Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ren Yamada

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Carcinogenesis|May 26, 2020
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signalingTaku Shigesawa, Osamu Maehara, Goki Suda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 7, 2022
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver diseaseAkihisa Nakamura, Koji Yamamoto, Rei Takeda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 25, 2024
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective studyZijian Yang, Goki Suda, Takuya Sho, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 30, 2022
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patientsMachiko Umemura, Koji Ogawa, Kenichi Morikawa, et al.
Frontiers in Genetics|May 23, 2022
Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial PneumoniaMichiko Takimoto-Sato, Toshinari Miyauchi, Masaru Suzuki, et al.
Scientific Reports|November 29, 2025
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohortGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 10, 2021
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Journal of Gastroenterology and Hepatology|March 19, 2020
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in JapanTakashi Kitagataya, Goki Suda, Kazunori Nagashima, et al.
Cancers|August 26, 2022
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150Takuya Sho, Goki Suda, Yoshiya Yamamoto, et al.
The Journal of Infection|February 28, 2026
Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective studyGoki Suda, Masatsugu Ohara, Masaru Baba, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Carcinogenesis|May 26, 2020
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signalingTaku Shigesawa, Osamu Maehara, Goki Suda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 7, 2022
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver diseaseAkihisa Nakamura, Koji Yamamoto, Rei Takeda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 25, 2024
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective studyZijian Yang, Goki Suda, Takuya Sho, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 30, 2022
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patientsMachiko Umemura, Koji Ogawa, Kenichi Morikawa, et al.
Frontiers in Genetics|May 23, 2022
Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial PneumoniaMichiko Takimoto-Sato, Toshinari Miyauchi, Masaru Suzuki, et al.
Scientific Reports|November 29, 2025
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohortGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 10, 2021
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Journal of Gastroenterology and Hepatology|March 19, 2020
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in JapanTakashi Kitagataya, Goki Suda, Kazunori Nagashima, et al.
Cancers|August 26, 2022
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150Takuya Sho, Goki Suda, Yoshiya Yamamoto, et al.
The Journal of Infection|February 28, 2026
Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective studyGoki Suda, Masatsugu Ohara, Masaru Baba, et al.
Pageof 5